Drugs / ARQ 736
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01225536 | Oct 2010 → Jan 2013 | cancer | ArQule, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARQ 736 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01225536 ↗ |
| Action | Inhibit | “Serine/threonine-protein kinase B-raf inhibitor” CHEMBL5316167 ↗1“Serine/threonine-protein kinase RAF inhibitor” CHEMBL5316167 ↗ |
| Modality | Small molecule | — CHEMBL5316167 ↗ |
| Route | Oral | “oral ARQ 736 administered” NCT01225536 ↗ |
| Target | BRAF | “Serine/threonine-protein kinase B-raf inhibitor” CHEMBL5316167 ↗ |
| Target | RAF1 | “Serine/threonine-protein kinase RAF inhibitor” CHEMBL5316167 ↗ |